Checkmate Pharmaceuticals is investigating the efficacy and safety of vidutolimod (CMP-001) in combination with checkpoint inhibitors in patients with various types of cancer, including melanoma and head and neck. To learn more about vidutolimod, a virus-like particle containing a CpG-A TLR9 agonist, visit our Science page.
We are recruiting eligible patients to participate in our ongoing immuno-oncology clinical trials with vidutolimod. For more information on our trials, please view the pages below or contact us at email@example.com.
Current Clinical Trials
A Multicenter, Open-label, Phase 2 Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Nivolumab in Subjects With Refractory Unresectable or Metastatic Melanoma
A Randomized, Open-label, Active-control, Phase 2/3 Study of First-line Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Nivolumab Compared to Nivolumab Monotherapy in Subjects With Unresectable or Metastatic Melanoma
Head and Neck Squamous Cell Carcinoma (HNSCC)
A Multicenter, Phase 2, Open-label Study of Intratumoral Vidutolimod (CMP-001) in Combination With Intravenous Pembrolizumab in Subjects With Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma